Studying HIV drug resistance in Mozambique
Part of Infections clinical trials.
This study looks for HIV drug resistance in people who have been on a specific first-line HIV medication (TLD) for at least 6 months and still have detectable virus. It aims to understand if resistance is developing so that better treatments can be planned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV and are on a first-line regimen called TLD (Tenofovir, Lamivudine, Dolutegravir) for at least 6 months
- You have had a viral load above 200 copies/mL for at least the last 3 months
- You do not have an active cancer
- You do not have any active opportunistic infections (infections that take advantage of a weakened immune system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to find the best way to treat or prevent malaria in children with HIV. It may also help children without HIV who live in areas where malaria is common.
This study looks at why some people with HIV on antiretroviral therapy still have small amounts of virus in their blood, while others achieve undetectable levels. Researchers will compare the two groups to understand the virus and immune system, which may help improve future treatments.
This study looks at whether certain genetic changes in the HIV virus (called drug resistance mutations) affect how well your immune system recovers after you start HIV treatment. It could help doctors understand why some people on HIV therapy have better immune recovery than others.
This study tests a new way of talking to people living with HIV about 'Undetectable = Untransmittable' (U=U) — meaning when HIV medicine makes the virus undetectable, it cannot be passed to others. It aims to make HIV counseling more helpful and supportive for people in South Africa.
This study tests a program to help people in Malawi stay on their HIV treatment even when they travel or move around. Researchers want to know if extra support can prevent gaps in care.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.